Our group has been studying the regulation of class I major histocompatibility complex (MHC) receptors in mouse (Ly49) and man (KIR) for many years, and we are pioneers in the identification of molecular mechanisms underlying the variegated expression of these receptors by NK cells. We have discovered many instances of genetic variation in KIR and Ly49 genes that can change the responsiveness of NK cells to MHC on target cells. However, our long-standing collaboration with the Carrington lab in the Cancer and Inflammation Program (CIP), has stimulated our interest in studying the expression of the KIR ligands, and the HLA-C gene in particular. Dr. Carrington's lab has demonstrated significant allelic variation in HLA-C expression, suggesting that both the receptors and ligands are involved in an evolutionary tuning process to produce optimal NK:target cell interactions. We have therefore conducted an extensive characterization of polymorphisms in HLA-C regulatory elements. In the past year, significant progress has been made in the investigation of the transcriptional control of HLA-C expression -a major ligand for the KIR family of human class I MHC receptors expressed by natural killer (NK) cells. We have identified and characterized a novel distal NK cell-specific HLA-C promoter. This discovery has important implications for the study of NK cell education by self MHC molecules. NK cell education has been a major focus in the field, and recent data has suggested a role for MHC expression by the NK cell itself in this process. Our work has defined a novel paradigm for cell-intrinsic regulation of NK cells by HLA-C, and we have discovered a complex system of tissue-specific alternative mRNA splicing that controls HLA-C expression by NK cells in different tissues. Furthermore, we have identified specific HLA-C alleles that have a single base pair polymorphism that inactivates the NK-specific promoter, resulting in reduced HLA-C expression by NK cells. We have found that this polymorphism has a significant effect on NK cell activity, and we are in the process of determining if hematopoietic stem cells donors that have low HLA-C expression on NK cells are associated with a distinct clinical outcome. This study is a component of our participation in a program project grant led by Dr. Jeffery Miller at the University of Minnesota. In addition, we have conducted a thorough analysis of allelic variation of transcription factor binding sites in the HLA-C gene, and identified multiple polymorphisms that account for the variation of HLA-C expression levels in peripheral blood lymphocytes that has been observed by the Carrington lab. Our detailed study of HLA-C has also revealed the presence of trophoblast-specific elements in the HLA-C gene that are not present in HLA-A or HLA-B genes, providing an explanation for the specific expression of HLA-C by trophoblasts. Future plans include: investigating the mechanism of NK cell-intrinsic tuning by HLA-C; using CRISPR technology to confirm functional role of the multiple KIR and HLA-C elements identified; studying clinical correlations of polymorphisms in the KIR and HLA genes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010013-24
Application #
10014323
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
24
Fiscal Year
2019
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Freund, Jacquelyn; May, Rebecca M; Yang, Enjun et al. (2016) Activating Receptor Signals Drive Receptor Diversity in Developing Natural Killer Cells. PLoS Biol 14:e1002526
Li, H; Wright, P W; McCullen, M et al. (2016) Characterization of KIR intermediate promoters reveals four promoter types associated with distinct expression patterns of KIR subtypes. Genes Immun 17:66-74
Felices, Martin; Lenvik, Todd R; Ankarlo, Dave E M et al. (2014) Functional NK cell repertoires are maintained through IL-2R? and Fas ligand. J Immunol 192:3889-97
Anderson, Stephen K (2014) Probabilistic bidirectional promoter switches: noncoding RNA takes control. Mol Ther Nucleic Acids 3:e191
Cichocki, Frank; Schlums, Heinrich; Li, Hongchuan et al. (2014) Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency. J Exp Med 211:1079-91
Wright, P W; Li, H; Huehn, A et al. (2014) Characterization of a weakly expressed KIR2DL1 variant reveals a novel upstream promoter that controls KIR expression. Genes Immun 15:440-8
O'Connor, Geraldine M; Vivian, Julian P; Widjaja, Jacqueline M et al. (2014) Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity. J Immunol 192:2875-84
Cichocki, Frank; Miller, Jeffrey S; Anderson, Stephen K et al. (2013) Epigenetic regulation of NK cell differentiation and effector functions. Front Immunol 4:55
Wright, P W; Huehn, A; Cichocki, F et al. (2013) Identification of a KIR antisense lncRNA expressed by progenitor cells. Genes Immun 14:427-33
Barao, Isabel; Wright, Paul W; Sungur, Can M et al. (2013) Differential expression of the Ly49G(B6), but not the Ly49G(BALB), receptor isoform during natural killer cell reconstitution after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 19:1446-52

Showing the most recent 10 out of 20 publications